Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420688 | 0.78 | NFE2L2 (0.52) | NFE2L2GCKALOX5PTGESGRM2 | |
| SCHEMBL4044221 | 0.76 | PDE3B (0.39) | ACACB | |
| SCHEMBL2194942 | 0.74 | NFE2L2 (0.48) | NFE2L2ALOX5PTGESGRM2LNPEP | |
| SCHEMBL2195417 | 0.72 | NFE2L2 (0.55) | NFE2L2ALOX5PTGESGRM2HPGD | |
| SCHEMBL7316232 | 0.72 | NFE2L2 (0.62) | NFE2L2GCKHPGD | |
| SCHEMBL30712982 | 0.71 | NFE2L2 (0.54) | NFE2L2ALOX5PTGESGRM2HPGD | |
| SCHEMBL2193147 | 0.71 | NFE2L2 (0.54) | NFE2L2ALOX5PTGESGRM2HPGD | |
| SCHEMBL13806577 | 0.71 | NFE2L2 (0.50) | NFE2L2ALOX5PTGESGRM2HPGD | |
| SCHEMBL2917239 | 0.71 | ITGB3 (0.60) | NFE2L2PPARGACACBHPGD | |
| SCHEMBL11893183 | 0.71 | NFE2L2 (0.60) | NFE2L2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | NFE2L2 1770/4885GCK 3637/4885ALOX5 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.